Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12856431 | 0.97 | TDP1 (0.68) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL6282770 | 0.91 | KMT2A (0.81) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL6160608 | 0.89 | KMT2A (0.58) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL10137663 | 0.89 | TDP1 (0.54) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL417403 | 0.88 | KMT2A (0.59) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| Hydrochloric Acid SCHEMBL2002861 | 0.88 | KMT2A (0.57) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL9051523 | 0.87 | NPC1 (0.61) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL913728 | 0.87 | TDP1 (0.69) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL6652699 | 0.87 | TDP1 (0.55) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL10137662 | 0.87 | KMT2A (0.55) | TDP1KMT2ASLC6A2SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3353152-B1 | METHOD | NORSK MEDISINSK SYKLOTRONSENTER AS (NO) | 2021-09-15 | — | — | EP | disclosed |
| EP-1583750-B1 | Macrocyclic beta-secretase inhibitors for treatment of Alzheimer's disease | MERCK SHARP & DOHME (US) | 2013-02-27 | — | — | EP | disclosed |
| US-7371853-B2 | Macrocyclic β-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO., INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7214712-B2 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-20060058278-A1 | Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME LLC | 2006-03-16 | — | — | US | disclosed |
| US-6995151-B2 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-02-07 | — | — | US | disclosed |
| US-20060025396-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | BARVIAN NICOLE C | 2006-02-02 | — | — | US | disclosed |
| EP-1583750-A2 | MACROCYCLIC BETA-SECRETASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1178969-B1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2005-07-13 | — | — | EP | disclosed |
| EP-1536786-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-08 | — | — | EP | disclosed |
| WO-1997032860-A1 | BENZODIAZONINE DERIVATIVES BINDING TO CHOLECYSTOKININ OR GASTRIN RECEPTORS | JAMES BLACK FOUNDATION LIMITED (GB) | 1997-09-12 | — | — | WO | disclosed |
| EP-0763026-A1 | GASTRIN AND CCK ANTAGONISTS | JAMES BLACK FOUNDATION LIMITED (GB) | 1997-03-19 | — | — | EP | disclosed |
| EP-0745673-A2 | Catalytic antibody regulated prodrug therapy | ZENECA LIMITED (GB) | 1996-12-04 | — | — | EP | disclosed |
| EP-0720601-A1 | GASTRIN AND CCK RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-07-10 | — | — | EP | disclosed |
| EP-0719251-A1 | BICYCLO (2.2.2) OCTANE DERIVATIVES CHOLECYSTOKININ AND/OR GASTRIN ANTAGONISTS | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-07-03 | — | — | EP | disclosed |
| US-5514683-A | LIGANDS FKOR CHOLECYSTOKININ OR GASTRIN RECEPTORS | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-05-07 | — | — | US | disclosed |
| WO-1995032949-A1 | GASTRIN AND CCK ANTAGONISTS | JAMES BLACK FOUNDATION LIMITED (GB) | 1995-12-07 | — | — | WO | disclosed |
| WO-1995030647-A1 | CCK AND GASTRIN RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1995-11-16 | — | — | WO | disclosed |
| WO-1995005359-A1 | BICYCLO (2.2.2) OCTANE DERIVATIVES CHOLECYSTOKININ AND/OR GASTRIN ANTAGONISTS | JAMES BLACK FOUNDATION LIMITED (GB) | 1995-02-23 | — | — | WO | disclosed |
| WO-1995004720-A2 | GASTRIN AND CCK RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 1995-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025396-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | MMP13, MMP11, MMP3 | TDP1 4305/4885KMT2A 3382/4885SLC6A2 575/4885 |
| US-20060058278-A1 | Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease | BACE1, BACE2, APP | TDP1 677/4885KMT2A 3961/4885SLC6A2 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.